CorMedix (CRMD) Non-Current Deferred Tax Liability (2025)

CorMedix's (CRMD) quarterly Non-Current Deferred Tax Liability came in at $144.6 million in Q4 2025, little changed quarter-over-quarter from $144.5 million in Q3 2025.

CorMedix (CRMD) Non-Current Deferred Tax Liability (2025) Analysis & Trends

CorMedix has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $144.6 million for Q4 2025.

  • Non-Current Deferred Tax Liability for Q4 2025 came in at $144.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $144.6 million (changed N/A YoY), and the FY2025 annual result was $144.6 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability came in at $144.6 million for Q4 2025 at CorMedix, roughly flat from $144.5 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $144.6 million in Q4 2025 to a low of $144.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 CorMedix 631,378.03 -154.57 Mn 107.31 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 144.63 Mn
Dec 31, 2025 144.63 Mn
Sep 30, 2025 144.53 Mn
Sep 30, 2025 144.53 Mn